Anlotinib combined with temozolomide for the treatment of patients with diffuse midline glioma: a case report and literature review

ABSTRACT:

Background

Diffuse midline glioma with a histone H3-K27M mutation is a brand-new tumor entity according to the 2016 edition of World Health Organization (WHO) classification. As diffuse midline gliomas are aggressive and incurable brain tumors, characterized by high levels of intrinsic and acquired resistance to therapy, as well as conventional treatment can hardly work due to an intact blood-brain barrier, leading to very poor outcomes for patients. Anlotinib is a multitarget tyrosine kinase inhibitor and has been used for the treatment of multiple tumor species, with satisfying outcomes. However, anlotinib has not been reported for the treatment of patients with diffuse midline glioma.

Case Description

This is a case report about a 51-year-old man suffering from diffuse

SUBMITTER: Feng Y 

PROVIDER: S-EPMC9641137 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature